At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 138 enrolled
Drug / intervention
Ibrutinib +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter Open-Label Phase 1b/2 Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib, in Combination With Lenalidomide and Rituximab in Subjects With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
In Brief
A Phase 2 clinical trial evaluating Ibrutinib, Lenalidomide, and 1 other intervention for Relapsed Diffuse Large B-Cell Lymphoma and Refractory Diffuse Large B-Cell Lymphoma. Completed, enrolled 138 participants across 40 sites in 4 countries.
Detailed Summary
This Phase 1b/2 study is designed to assess the safety and efficacy of ibrutinib in combination with lenalidomide and rituximab in subjects with relapsed/refractory diffuse large B-cell lymphoma (DLBCL) not eligible for transplant.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesBelgium, Germany, United Kingdom, United States
CollaboratorsJanssen Research & Development, LLC, Celgene Corporation
Timeline
Phase 2CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 2014
Enrollment StartMar 2014
Primary CompletionDec 2020
TodayJul 2026
First PostedMar 4, 2014
Enrollment StartMar 13, 2014
Primary CompletionDec 17, 2020
TodayJul 2, 2026
Enrollment to primary: 6.8 yearsPosted 12.3 years ago
Interventions
Ibrutinibdrug
Lenalidomidedrug
Rituximabdrug